Jasper Therapeutics reports Q2 2026 results after closing Kira Pharmaceuticals merger

Jasper Therapeutics said on July 16, 2026, it completed the acquisition of Kira Pharmaceuticals, a former Cayman limited company that had been developing complement therapies for immune-mediated diseases, structured as an all-stock deal.¹ Alongside the deal, Jasper sold non-voting convertible preferred stock in a private placement led jointly by Affinity Asset Advisors, LLC and Ikarian Capital LLC, with other life science investors also participating, generating roughly $132 million in gross proceeds.¹

The combined pipeline now centers on three programs. KP-104 (vensobafusp alfa), a bifunctional complement inhibitor targeting both the alternative and terminal pathways, is being tested for PNH and rare renal disorders; it is currently in a Phase 2 basket trial in rare renal indications, with interim Stage 1 data expected in the fourth quarter of 2026.¹ Citing earlier positive results in treatment-naive PNH patients, the company plans an end-of-Phase 2 meeting with the FDA and expects to disclose next steps for PNH development in the first half of 2027.¹

For briquilimab, an anti-KIT antibody, the company pointed to positive long-term SCID data and said it is working toward a pre-BLA meeting with the FDA, with an update on next steps targeted for the first quarter of 2027.¹ The third asset, KP-701, a dual-acting anti-CD79BxCD32B monoclonal antibody for autoantibody-mediated disorders, is expected to reach a CTA and/or IND filing for Phase 1 testing in the first quarter of 2027.¹

On finances, cash and cash equivalents stood at $7.3 million as of June 30, 2026.¹ The company said the $132 million financing gives it capital to fund planned operations through the second half of 2028.¹ Jasper reported a net loss of $2.8 million for the quarter, or $0.10 per basic and diluted share.¹